The purpose of this Bill is to make provision for primary health care services without charge for persons who have contracted hepatitis C directly or indirectly from the use of human immunoglobulin — anti-D — or the receipt within the State of another blood product or a blood transfusion. The services to be provided include: general practitioner services, including prescribed drugs and medicines; dental, ophthalmic and aural services; counselling services; home help services; and home nursing services.
When the possible link between the anti-D product and hepatitis C was brought to the attention of the Department of Health in February 1994 the immediate concerns were the protection of all future recipients of anti-D and the identification of any risk for any mother who had received the anti-D product in the past. The first objective was met by the immediate introduction of a new virally inactivated anti-D product to all maternity hospitals and units. The second objective was met by the national screening programme for anti-D recipients, launched by the Blood Transfusion Services Board (BTSB), which offered screening for hepatitis C for anti-D recipients.
Some 60,316 women who received anti-D between 1970 and February 1994 have been screened under the national blood screening programme and 994 have tested positive for hepatitis C antibodies, of whom 472 have tested positive for the virus.
A targeted lookback programme was also undertaken by the BTSB to identify persons who had contracted hepatitis C from a blood transfusion. Some 266 living recipients of medium/high risk donations have been traced to date under this programme. Testing for hepatitis C antibodies has been carried out on 208 persons and 122 of these 208 are antibody positive. Testing for hepatitis C virus has been carried out on 183 persons. Some 73 of these persons have evidence of continuing hepatitis C infection.
The optional testing programme commenced in early September 1995 to trace a small number of persons who may have contracted hepatitis C from a blood transfusion and who would not be traced under the targeted lookback programme. Some 10,439 persons have come forward for testing to date and 34 of these persons have been confirmed positive for hepatitis C antibodies and 19 of 21 tested, are positive for hepatitis C virus.
The Government is committed to providing a high quality health service for all persons who have contracted hepatitis C from a blood transfusion or a blood product. Substantial progress has already been made over the last two years in meeting the many complex and varied health care needs of those persons who have contracted hepatitis C. This has been made possible by a process of consultation between the Department of Health and Positive Action, a support group for Anti-D women and their families, Transfusion Positive, a support group for blood transfusion recipients and their families, the Irish Kidney Association and the Irish Haemophilia Society. Many of the concerns expressed by these groups in relation to future health care arrangements have been addressed.
The special health care programme involves an extensive range of services in the following areas: secondary health care services, primary health care services, special research programme and a statutory monitoring body. Secondary health care treatment for those persons who have contracted hepatitis C from a blood product or blood transfusion is being provided since early 1994 at special consultant staffed clinics at six designated hospitals — St James's Hospital, Dublin, Beaumont Hospital, Dublin, Mater Hospital, Dublin, St, Vincent's Hospital, Dublin, Cork University Hospital and University College Hospital, Galway.
Specific funding has been provided in the Book of Estimates each year to ensure the consolidation and maintenance into the future of a high quality hospital in-patient and out-patient service, including prescribed medication for persons who have contracted hepatitis C from a blood transfusion or blood product. The secondary care element of the health care services programme includes provision for access to in-patient and out-patient treatment; non-payment of hospital charges; appropriate staffing levels and arrangements for staff training; equipment for hepatitis C units; anti-viral therapies and therapy initiation programmes; liver transplantation; treatment outside of Ireland where necessary; liaison between the hospital service providers; and prompt referral to clinicians for conditions associated with hepatitis C. The treatment services are also available to children and partners who are hepatitis C positive. The Health Act, 1970, is the statutory basis for the provision of these services.
The Government recognises the need for specific research in relation to hepatitis C, particularly in view of the fact that hepatitis C was described for the first time in 1989 and that a reliable screening test had only become available in 1991. My colleague, Deputy Noonan, Minister for Health, has arranged with the Health Research Board for the establishment of a special programme of research on hepatitis C and has provided special funding of £100,000 to enable this programme to commence this year.
To ensure that the health service as it relates to persons who have contracted hepatitis C from a blood product or blood transfusion is responsive to the changing needs of such patients, the Minister for Health is establishing a statutory consultative council which will advise him on matters relating to hepatitis C. The functions of the consultative council will include the monitoring of health and counselling services for persons with hepatitis C; the making of recommendations on the organisation and delivery of services for persons with hepatitis C; publication of information on hepatitis C; and liaison with the Health Research Board in relation to the special programme of hepatitis C research projects.
The Minister for Health has circulated a draft establishment order to interested groups for their views. Following this consultation process, amendments to the draft establishment order are being considered to take into account the views expressed by these groups. The Minister will again consult with the interested groups at an early date and following such consultation will formally establish the council. The secondary health care services, the consultative council and the research programme do not require new legislation as there is already statutory provision for these initiatives.
As I have already indicated, the purpose of the Health (Amendment) Bill, 1995, is to make provision for primary health care services without charge to persons who have contracted hepatitis C directly or indirectly from the use of human immunoglobulin anti-D or the receipt within the State of another blood product or a blood transfusion. The primary health care services to be provided by the Bill free of charge and without a means test are general practitioner services; drugs, medicines and medical and surgical appliances; dental, ophthalmic and aural services and dental, optical and aural appliances; counselling services in respect of hepatitis C; home help services; home nursing services; and such other services as may be prescribed.
In relation to the general practitioner services, eligible persons may attend the general practitioner of their choice for all medical conditions. Drugs, medicines and medical and surgical appliances will be provided to them free of charge for all medical conditions. The Bill also proposes that dental, ophthalmic and aural services will be provided without charge for eligible persons. Counselling services, as described in the health care package which was published in December 1995, will be made available to eligible persons.
Home help services within the meaning of section 61 of the Health Act, 1970, and home nursing services within the meaning of section 60 of the Health Act, 1970, will also be provided free of charge to persons who have contracted hepatitis C from a blood transfusion or a blood product. These arrangements will also apply to the children and partners of persons who have contracted hepatitis C from a blood product or a blood transfusion if such children and partners have also been diagnosed positive for hepatitis C.
Arrangements will also be made with each of the health boards to designate a specific officer to act as a contact points for individuals and also as a liaison officer with each of the various interest groups whose members will be availing of the services set out in the Bill.
The Bill provides at section 2 that health boards shall make available certain health services without charge to persons who have contracted hepatitis C directly from the use of human immunoglobulin anti-D or the receipt within the State of another blood product or blood transfusion. The chief executive officer of the relevant health board will determine eligibility at his discretion. It is envisaged that his decision will involve inter alia, consideration of medical opinion submitted by the applicant's treating physician and also that of the board's director of public health. This provision is intended to allay fears of some members of Transfusion Positive who expressed concern about possible difficulties in the acquisition of past medical records and the determination of proof of contraction of hepatitis C from a blood transfusion.
As I have already outlined, a range of services will be provided under the Act and preliminary discussions have already taken place with some of the relevant bodies. Detailed negotiations cannot commence until the necessary legislation is in place. As soon as the Bill has passed all Stages in both Houses, it is hoped that discussions with health boards and negotiations with appropriate professional groups will be finalised to ensure the services to be provided under the Act for persons who have been diagnosed positive for hepatitis C will be available to them at an early date. The commencement order provision in section 1 (3) will allow time to finalise the necessary arrangements to ensure the provision of a high quality primary health care service. Undue delays in the regard are not anticipated.
In addition to providing for the health care needs of these persons, the Government, as the Senators are aware, is fully committed to fair compensation for persons who have contracted hepatitis C from a blood product or blood transfusion. The Minister for Health established the compensation tribunal on 15 December 1995 and the closing date for receipt of applications is Monday next, 17 June.
For the information of the Seanad, the total number of persons with hepatitis C who received a blood transfusion or blood product who have been identified to date is 1,356. The compensation tribunal has up to yesterday evening received 817 applications and I have been informed by the tribunal that a substantial additional number of applications is expected before the closing date. Since its commencement the tribunal has heard 70 cases. The awards made to date by the tribunal range from £15,500 to £324,321. A sum of approximately £7.5 million has been awarded to date by the compensation tribunal and no tribunal award has been rejected. Payment of an award is made within 28 days of receipt by the tribunal of notification of acceptance of an award. The tribunal is running smoothly, fairly and efficiently, as had been envisaged, and at this stage it has hearing dates arranged until 31 July 1996.
The Health (Amendment) Bill, 1995, will copperfasten the Government's commitment to meeting the future health care needs of persons who have contracted hepatitis C from a blood transfusion or blood product. The health care services at primary and secondary care levels will meet the genuine concerns in relation to the continued provision of high quality health care into the future for those who have contracted hepatitis C. I commend the Bill to the House.